Agios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies Read more about Agios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies
Agios Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference Read more about Agios Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors Read more about Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors
Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting Read more about Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting
Agios Reports Third Quarter 2015 Financial Results Read more about Agios Reports Third Quarter 2015 Financial Results
Agios to Present at Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10 Read more about Agios to Present at Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10
Agios to Webcast Conference Call of Third Quarter 2015 Financial Results on November 5, 2015 Read more about Agios to Webcast Conference Call of Third Quarter 2015 Financial Results on November 5, 2015
Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC Read more about Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC
Agios Outlines Key Clinical Development & Research Strategies Read more about Agios Outlines Key Clinical Development & Research Strategies
Agios to Webcast R&D Day on October 16, 2015 Read more about Agios to Webcast R&D Day on October 16, 2015